Systemic review on safety of Tongxinluo Capsules

ZHANG Yao-wen,FANG Ren-fei,YANG Chao,WU Zhi-jun,LI Tong-tong,WU Zong-gui,DONG Qiang

DOI: https://doi.org/10.3969/j.1674-4055.2013.04.005

2013-01-01

Abstract:Objective To review systematically the safety of Tongxinluo Capsules. Methods The databases were retrieved with computer including Chinese BioMedical Database (CBM), China National Knowledge Infrastructure (CNKI), Chinese Science and Technique Journals Database (VIP), Wanfang database, Cochrane Library and PubMed, and the“Adverse Drug Reaction Information Bulletin”released by Chinese Adverse Drug Reaction Monitoring Center was received manually from Jan. 2013 to May, 2013. Literature screening, quality assessment and data extraction were followed by inclusion and exclusion criteria. The clinical experimental literature was given a Meta-analysis by applying MetaAnalyst 3.13, and others were reviewed with descriptive analysis. Results There were 144 clinical studies included, and totally 6254 cases had Tongxinluo Capsules and 6006 had not. The incidence of adverse nervous system events was lower in the patients only taking Tongxinluo Capsules than those only taking chemical drugs compared with other chemical drugs or Chinese medicinal. For other types of adverse events, Tongxinluo Capsules was faired to chemical medicine or other Chinese medicinal. In 15 case-series studies, there were totally 701 patients taken Tongxinluo Capsules, of them 52 with gastrointestinal adverse events and 1 with dermatitis or rash adverse event. One case of dermatitis or rash adverse event was reported in two case reports. Conclusion The safety of Tongxinluo Capsules is acceptable, and the adverse drug reaction/event monitoring should be strengthened for providing high quality evidence for clinical application of Tongxinluo Capsules.